The FDA has granted fast track designation to emiltatug ledadotin for advanced or metastatic breast cancer treatment, as ...

The top-line results of DESTINY Breast-04 are impressive - in patients with HER2-low metastatic breast cancer who received multiple lines of prior treatment, Enhertu (trastuzumab deruxtecan ...

HER2-negative breast cancers are HER2-low and potentially an additional 25% may be HER2-ultra-low. There are no targeted therapies specifically approved for patients with HER2-ultra-low expression ...

Mersana shares Phase 1 data on Emi-Le for TNBC and details FDA's Fast Track status for XMT-1660 in advanced HER2-low breast ...

REVEAL GENOMICS, S.L., a Barcelona-based biotechnology start-up seeking to revolutionize precision oncology through biomarker ...

Mersana Therapeutics (MRSN) stock hits a 52-week low in reaction to early clinical results for its cancer drug Emi-Le in ...

Daiichi Sankyo's stock dropped 25% due to disappointing clinical data, but upcoming studies could drive a rebound for ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

Conference call to discuss positive initial Phase 1 clinical data today at 8:30 a.m. ETCAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE ...

NEW YORK – Eli Lilly on Monday said it will acquire Scorpion Therapeutics' mutant-PI3Kα inhibitor STX-478 for up to $2.5 billion while Scorpion spins out a new entity to develop its non-PI3Kα assets.

Medscape Medical News, December 19, 2024 SABCS 2024 T-DXd Effective in HR+/HER2-Low BC After Endocrine Failure New DESTINY-Breast06 analysis showed trastuzumab deruxtecan doubled PFS versus ...

Mark Agulnik, MD, discusses the efficacy and adverse events in the DeFi trial for patients with desmoid tumors given nirogacestat.